NCT00805610

Brief Summary

The investigators research will examine the safety and efficacy of hepatocyte transplantation in the patient with acute liver failure without history of chronic disease. The investigators will study the effectiveness in providing a bridge of support for patient survival until whole organ transplantation is possible. This support may also be a bridge to recovery; by allowing the native liver to recover so that orthotopic liver transplant is not necessary. The investigators will also study the safety and efficacy of hepatocyte transplantation in the patient with chronic liver disease. Underlying etiologies of chronic disease may arise from cirrhosis, fibrosis or inherited metabolic disorders. The investigators will examine cell transplantation in end-stage patients not eligible for whole organ transplant. These patients may benefit with an amelioration of symptoms that will allow other therapeutic treatments. The investigators study will also examine the ability of transplanted hepatocytes to treat inherited metabolic diseases (ex., Crigler-Najjar Disease, Familial Hypercholesterolemia, Urea Cycle Disorders). Cell transplant may also act as a 'bridge' to whole organ transplant or improve function, permitting easier disease control through traditional therapy.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2014

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 5, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 9, 2008

Completed
5.5 years until next milestone

Study Start

First participant enrolled

June 1, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

August 5, 2014

Status Verified

August 1, 2014

Enrollment Period

2 years

First QC Date

December 5, 2008

Last Update Submit

August 1, 2014

Conditions

Keywords

Liver FailureHepatocyte TransplantationLiver Transplantation

Outcome Measures

Primary Outcomes (1)

  • The functional capability of transplanted hepatocytes to assume function in the native liver.

    Outcome measurements will be assessed weekly through week two post transplant, then monthly through month 12, then every six months.

Study Arms (1)

Hepatocyte Transplantation

EXPERIMENTAL

Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.

Biological: Hepatocyte Transplantation

Interventions

Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.

Hepatocyte Transplantation

Eligibility Criteria

AgeUp to 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may not qualify if:

  • Any systemic infection
  • Unstable coronary artery disease
  • HIV infection
  • Preformed antibodies to class antigens that are present on all available donor samples (Only cells from an ABO-compatible donor with no HLA Class I antigen to which the recipient has preformed antibodies will be selected for transplant.)
  • Hepatopulmonary disease (Room air Pa02 ≤ 60 mmHg)
  • Testing positive for Hepatitis B Surface Antigen (HBsAg), Hepatitis Be antigen (HBeAg) or Hepatitis B Virus by DNA and unable to receive or pay for Hepatitis B treatment.
  • Any current or anticipated contraindication for the use of tacrolimus and cyclosporine, methylprednisolone or prednisone.
  • Female patients who are breast feeding
  • Any medical condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Virginia Commonwealth University Health System

Richmond, Virginia, 23298, United States

Location

MeSH Terms

Conditions

Liver Failure

Condition Hierarchy (Ancestors)

Hepatic InsufficiencyLiver DiseasesDigestive System Diseases

Study Officials

  • Robert A Fisher, M.D.

    Virginia Commonwealth University Health System

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2008

First Posted

December 9, 2008

Study Start

June 1, 2014

Primary Completion

June 1, 2016

Study Completion

June 1, 2018

Last Updated

August 5, 2014

Record last verified: 2014-08

Locations